Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.

History
The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became lion bio Pharma, then rebranded to Iovance in 2017.

In 2024 the US FDA gave accelerated approval to Lifileucel, the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma.